<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815360</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00002813</org_study_id>
    <nct_id>NCT00815360</nct_id>
  </id_info>
  <brief_title>Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion</brief_title>
  <acronym>RaScaL</acronym>
  <official_title>Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Associates of Florida, P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Associates of Florida, P.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of ranibizumab and angiographically-directed peripheral scatter laser&#xD;
      therapy in patients with clinically-significant diabetic macular edema (CSME) and peripheral&#xD;
      nonperfusion. We propose a novel treatment of CSME in a subgroup of patients defined by a&#xD;
      combination of ultrawide-field angiography (UWFA) and optical coherence tomography (OCT).&#xD;
      Within this classification scheme, patients with CSME are subdivided by the presence of: 1)&#xD;
      focal macular leakage, 2) vitreomacular interface traction, and/or 3) peripheral&#xD;
      nonperfusion. The successful treatment of diabetic macular edema would be dictated by&#xD;
      pathophysiology-directed therapy based on this classification.&#xD;
&#xD;
      The subgroup of interest for this clinical trial is characterized by diabetic macular edema,&#xD;
      peripheral nonperfusion on UWFA, and the absence of macular traction on OCT. This group of&#xD;
      patients has previously not been well recognized or characterized due to limitations in&#xD;
      previous, standard angiographic evaluation of the retinal periphery.&#xD;
&#xD;
      We postulate that this subcategory represents one with a high rate of failure of accepted&#xD;
      therapies given persistence of the basic pathophysiologic mechanism for CSME, namely&#xD;
      ischemia-induced production of Vascular Endothelial Growth Factor (VEGF) from the retinal&#xD;
      periphery. This also represents a population of patients with likely recurrence of CSME&#xD;
      despite treatment with anti-VEGF therapy alone for the same reason.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy is a leading cause of moderate and severe visual loss in developed&#xD;
      countries. It is of paramount socioeconomic impact as the prevalence of diabetes is sharply&#xD;
      increasing, diabetic macular edema is the leading cause of vision loss in working age&#xD;
      patients, it is a significant cause of vision loss in patients older than 65 years of age, it&#xD;
      frequently affects patients bilaterally, and the costs of therapy are increasing.&#xD;
&#xD;
      Diabetic macular edema (DME) is the most common cause of vision loss in diabetic retinopathy.&#xD;
      The pathophysiology of DME is complex and multifactorial. Chronic hyperglycemia, protein&#xD;
      kinase C (PKC) formation, free radical accumulation, advanced glycation end-product (AGE)&#xD;
      proteins, and ischemia-driven release of vascular endothelial growth factor (VEGF) are some&#xD;
      of the better understood factors that contribute to chronic retinal arterial and capillary&#xD;
      damage and increased permeability.&#xD;
&#xD;
      The RIDE and RISE Studies demonstrated the superiority of anti-VEGF monotherapy with&#xD;
      ranibizumab over sham therapy, when all groups were allowed to receive macular laser therapy&#xD;
      after month 3 based on predefined criteria. Furthermore, other studies have demonstrated VEGF&#xD;
      inhibitors to be beneficial for DME, either as monotherapy or in combination with macular&#xD;
      laser.&#xD;
&#xD;
      The benefit of VEGF antagonists in treating DME validates that the VEGF pathway is a key&#xD;
      target. The need for repeated anti-VEGF injections to maintain the benefit of treatment begs&#xD;
      the question whether persistent peripheral retinal ischemia may be driving VEGF production in&#xD;
      at least a subset of patients with DME. Fluorescein angiographic studies of the mid- and&#xD;
      far-periphery of diabetic patients by Shimizu in the 1980's demonstrated areas of peripheral&#xD;
      retinal nonperfusion in diabetic patients. These findings have been reproduced and&#xD;
      substantiated more recently utilizing a novel, commercially-available imaging system for&#xD;
      ultrawide-field angiography (UWFA) that employs a scanning laser ophthalmoscope and an&#xD;
      ellipsoidal mirror.&#xD;
&#xD;
      We investigated whether patients with diabetic macular edema associated with peripheral&#xD;
      nonperfusion on UWFA would have improved visual acuity, resolution of retinal thickening on&#xD;
      OCT, and durability of therapy using a novel strategy of a single intravitreal injection of&#xD;
      Ranibizumab, a VEGF-A inhibitor + UWFA-guided peripheral Scatter Laser, or RaScaL. A second&#xD;
      goal of the study was to guide DME treatment by the imaging signature of UWFA and OCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)&#xD;
peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)&#xD;
macular laser per treatment criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of ranibizumab</intervention_name>
    <description>intravitreal injection of 0.5 mg ranibizumab</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral laser</intervention_name>
    <description>ultra-widefield fluorescein angiography guided peripheral laser</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>treatment arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of triamcinolone acetonide</intervention_name>
    <description>intravitreal injection of 4.0 mg triamcinolone acetonide</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>control arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>macular laser</intervention_name>
    <description>macular laser to areas of retinal thickening or leakage</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be eligible if the following criteria are met:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Patient related considerations:&#xD;
&#xD;
        • Patients with Type I or Type II diabetes&#xD;
&#xD;
        Disease related considerations:&#xD;
&#xD;
          -  Study eye with clinically significant diabetic macular edema characterized by macular&#xD;
             edema, peripheral nonperfusion, and absence of macular traction on clinical exam,&#xD;
             UWFA, and OCT.&#xD;
&#xD;
          -  Study eye with best corrected visual acuity between 20/40 (≤ 73 letters on Early&#xD;
             Treatment of Diabetic Retinopathy Study (ETDRS) chart and 20/320 (≥ 19 letters on&#xD;
             ETDRS chart) Other considerations&#xD;
&#xD;
          -  Patient able to complete all study visits&#xD;
&#xD;
          -  Female patients must be using two forms of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation. Premenopausal women not using&#xD;
             adequate contraception. The following are considered effective means of contraception:&#xD;
             surgical sterilization or use of oral contraceptives, barrier contraception with&#xD;
             either a condom or diaphragm in conjunction with spermicidal gel, an Intra Uterine&#xD;
             Device, or contraceptive hormone implant or patch.&#xD;
&#xD;
          -  Prior enrollment in the study&#xD;
&#xD;
          -  Any other condition that the investigator believes would pose a significant hazard to&#xD;
             the subject if the investigational therapy were initiated&#xD;
&#xD;
          -  Participation in another simultaneous medical investigation or trial&#xD;
&#xD;
          -  Therapy with intravitreal triamcinolone, pegaptanib, ranibizumab, or bevacizumab&#xD;
             within the previous 3 months&#xD;
&#xD;
          -  Previous panretinal scatter laser photocoagulation&#xD;
&#xD;
          -  Previous pars plana vitrectomy&#xD;
&#xD;
          -  Visually-significant significant cataracts as primary reason for vision loss&#xD;
&#xD;
          -  Uncontrolled or advanced glaucoma&#xD;
&#xD;
          -  Patients on more than one anti-glaucoma agent&#xD;
&#xD;
          -  Myocardial infarction or cerebrovascular accident within 6 months&#xD;
&#xD;
          -  Subjects with poor glycemic control that have initiated intensive insulin treatment or&#xD;
             plan to do so in the next 4 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan J Suner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Associates of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Associates of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>December 26, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <results_first_submitted>May 23, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2015</results_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Associates of Florida, P.A.</investigator_affiliation>
    <investigator_full_name>Ivan J. Suner, MD</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>diabetic macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on Ultra Widefield Fluorescein Angiography (UWFA).</recruitment_details>
      <pre_assignment_details>Treatment naive patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>ranibizumab and scatter laser</description>
        </group>
        <group group_id="P2">
          <title>Comparative Group 1</title>
          <description>Intravitreal triamcinolone with macular laser</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group 1</title>
          <description>ranibizumab and scatter laser</description>
        </group>
        <group group_id="B2">
          <title>Comparative Group 1</title>
          <description>Intravitreal triamcinolone with macular laser</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="7.5"/>
                    <measurement group_id="B2" value="58.3" spread="6.5"/>
                    <measurement group_id="B3" value="58.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.</title>
        <time_frame>6 months</time_frame>
        <population>We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on UWFA.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>ranibizumab and scatter laser</description>
          </group>
          <group group_id="O2">
            <title>Comparative Group 1</title>
            <description>Intravitreal triamcinolone with macular laser</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.</title>
          <population>We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on UWFA.</population>
          <units>Letters of visual acuity on ETDRS chart</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9" upper_limit="15"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>ranibizumab and scatter laser</description>
          </group>
          <group group_id="O2">
            <title>Comparative Group 1</title>
            <description>Intravitreal triamcinolone with macular laser</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months</title>
          <units>units on a scale (microns)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="240" upper_limit="310"/>
                    <measurement group_id="O2" value="350" lower_limit="280" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group 1</title>
          <description>Intravitreal ranibizumab and peripheral laser</description>
        </group>
        <group group_id="E2">
          <title>Comparative Group 1</title>
          <description>Intravitreal triamcinolone acetonide and macular laser</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small study size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ivan J. Suner</name_or_title>
      <organization>Retina Associates of Florida, P.A.</organization>
      <phone>813-875-6373</phone>
      <email>ivansuner@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

